Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Research and analysis highlights
Momenta Pharmaceuticals's is focused on the development of generic and novel drugs. The company has developed an integrated technology solution that addresses many of the challenges associated with creating drugs based on complex sugars.
It currently has investigational compounds in clinical development for a wide range of diseases, including acute coronary syndrome, thrombosis, multiple sclerosis and cancer. In addition, the company has entered into collaboration with Sandoz for the joint development, manufacture and commercialization of certain of these compounds.
Momenta Pharmaceuticals derives 100% of its revenues under collaboration and licensing agreement with Sandoz. During the period 2003-2006, the company's total revenues increased from $1 million to $16 million. Prior to 2003, the company did not record any revenues, as its collaboration agreement with Sandoz commenced only in 2003.
Key reasons to read this report
Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization
For more information kindly visit: http://www.bharatbook.com/
